This study tests whether adding an experimental drug (INBRX-106) to the standard immunotherapy pembrolizumab works better than pembrolizumab alone for people with advanced head and neck cancer that has spread or come back. About 410 adults whose tumors have a high level of a prot…
Phase: PHASE2, PHASE3 • Sponsor: Inhibrx Biosciences, Inc • Aim: Disease control
Last updated May 01, 2026 15:57 UTC